Peri-ablation warfarin vs. dabigatran: Different but the same

Europace

Volumn 15, Issue 10, 2013, Pages 1385-1386

  Winkle, Roger A ^a,b   Kong, Melissa H ^a,b  

^a Silicon Valley Cardiology   (United States)

^b SEQUOIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIAC PATIENT; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INSURANCE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; THROMBUS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CATHETER ABLATION; HUMANS; PYRIDINES;

EID: 84884991574     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut295     Document Type: Editorial

References (9)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, ParekhAet al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
2. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. New Engl J Med 2011;364:806-17.
3. Patel MR, MahaffeyKW, Garg J, Pan G, Singer DE, HackeWet al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
4. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2011;24:264-8.
5. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63.
6. Lakkireddy D, Reddy YM, Di Base L, Vanga SR, Santageli P, Swarup V et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2012;59: 1168-74.
7. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15: 1407-11.
8. Abdulhak AAB, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwarlt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15:1412-20.
9. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013;6:651-8.